5Nelson EC,Evans CP,Lara PN Jr. Renal cell carcinoma: cur-rent status and emerging therapies [ J]. Cancer Treat Rev,2007,33(3):299-313.
6Staehler M, Rohrmann K, Haseke N, et al. Targeted agents forthe treatment of advanced renal cell carcinoma [ J]. Chit DrugTargets, 2005, 6(7) :835 -846.
7Bellmunt J. Sunitinib in advanced renal cell carcinoma: clinicalevidence [J]. Eur Urol,2008,7(Suppl 9) :585 -592.
8Finke J, Ko J, Rini B, et al. MDSC as a mechanism of tumorescape from sunitinib mediated anti-angiogenic therapy [ J]. IntImmunopharmacol,2011,11 (7) :856 -861.
9Gmwald V,Heinzer H, Fiedler W. Managing side effects ofangiogenesis inhibitors in renal cell carcinomal [ J ]. Onkologie,2007,30 (10) : 519-524.
